Filament Health signs UC San Francisco phase 2 psilocybin trial license
Rhelion Life Sciences says its wholly owned subsidiary Filament Health signed a licence agreement with the University of California, San Francisco for a Phase 2 trial of psilocybin in methamphetamine use disorder among people with HIV.